Home › Triple-Negative Breast Cancer
Triple-Negative Breast Cancer clinical trials recruiting in the U.S.
147 studies for Triple-Negative Breast Cancer are recruiting participants at sites across the United States.
Cities with the most studies
- Houston, TX42 studies
- New York City, NY31 studies
- Nashville, TN28 studies
- Los Angeles, CA27 studies
- Boston, MA26 studies
- San Antonio, TX23 studies
- St. Louis, MO21 studies
- Atlanta, GA20 studies
- Arlington, VA20 studies
- Dallas, TX18 studies
- Chicago, IL16 studies
- Columbus, OH16 studies
- Tampa, FL15 studies
- Grand Rapids, MI15 studies
- New Haven, CT15 studies
- Queens, NY15 studies
- Seattle, WA14 studies
- Philadelphia, PA13 studies
- Austin, TX13 studies
- San Diego, CA13 studies
- West Valley City, UT13 studies
- Durham, NC12 studies
- Denver, CO12 studies
- Orlando, FL12 studies
- Baltimore, MD12 studies
- Rochester, MN11 studies
- Washington, DC11 studies
- Pittsburgh, PA11 studies
- Edison, NJ11 studies
- Miami, FL11 studies
- San Francisco, CA11 studies
- Cleveland, OH10 studies
- Baldwin Park, CA10 studies
- Salt Lake City, UT9 studies
- Oklahoma City, OK9 studies
- Jacksonville, FL9 studies
- Detroit, MI9 studies
- Indianapolis, IN9 studies
- Aurora, CO9 studies
- Portland, OR9 studies
By state
- Alabama11 studies
- Arizona18 studies
- Arkansas3 studies
- California53 studies
- Colorado21 studies
- Connecticut19 studies
- Delaware3 studies
- District of Columbia7 studies
- Florida47 studies
- Georgia26 studies
- Illinois20 studies
- Indiana13 studies
- Iowa8 studies
- Kansas5 studies
- Kentucky6 studies
- Louisiana6 studies
- Maine3 studies
- Maryland18 studies
- Massachusetts26 studies
- Michigan28 studies
- Minnesota17 studies
- Missouri24 studies
- Nebraska6 studies
- Nevada6 studies
- New Jersey20 studies
- New Mexico3 studies
- New York46 studies
- North Carolina21 studies
- Ohio29 studies
- Oklahoma10 studies
- Oregon12 studies
- Pennsylvania23 studies
- Rhode Island4 studies
- South Carolina9 studies
- South Dakota7 studies
- Tennessee31 studies
- Texas59 studies
- Utah23 studies
- Virginia28 studies
- Washington20 studies
- Wisconsin7 studies
Recently updated studies
The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
RecruitingPhase 1/2
Ages 12 and older · All sexes · Updated Oct 2, 2026 · NCT04585750A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Oct 2, 2026 · NCT06465069A Phase 1 Study of PLN-101095 in Adults With Advanced or Metastatic Solid Tumors
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Oct 2, 2026 · NCT06270706Collection of CSF Samples From Participants With Metastatic Triple Negative Breast Cancer (TNBC) and HER2+ Breast Cancer With no Prior History Nor Active Radiographically Detectable Brain Metastases
RecruitingObservational study
Ages 18 to 120 · All sexes · Updated Oct 2, 2026 · NCT07619534A Study With NKT3964 for Adults With Advanced/Metastatic Solid Tumors
RecruitingPhase 1
Ages 19 and older · All sexes · Updated Oct 1, 2026 · NCT06586957177Lu-BetaBart in Patients With Relapsed/Refractory, Locally Advanced Inoperable, or Metastatic Solid Tumors
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Oct 1, 2026 · NCT07189871PRE-ISPY Phase I/II Oncology Platform Program
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Sep 30, 2026 · NCT05868226Testing the Addition of Anti-Cancer Drug, ZEN003694 (ZEN-3694) and PD-1 Inhibitor (Pembrolizumab), to Standard Chemotherapy (Nab-Paclitaxel) Treatment in Patients With Advanced Triple-Negative Breast Cancer
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Sep 30, 2026 · NCT05422794First-in-Human Study of ATX-295, an Oral Inhibitor of KIF18A, as Monotherapy and in Combination With Anticancer Therapy in Patients With Advanced or Metastatic Solid Tumors, Including Ovarian Cancer
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Sep 29, 2026 · NCT06799065Study of AVZO-021 in Patients With Advanced Solid Tumors
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Sep 28, 2026 · NCT05867251Multicenter Trial for Eliminating Breast Cancer Surgery or Radiotherapy in Exceptional Responders to Neoadjuvant Systemic Therapy
Recruiting
Ages 30 and older · Women · Updated Sep 25, 2026 · NCT02945579A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 25, 2026 · NCT06966700Solid Tumor Analysis for HLA Loss of Heterozygosity (LOH) and Apheresis for CAR T- Cell Manufacturing
RecruitingObservational study
Ages 18 and older · All sexes · Updated Sep 25, 2026 · NCT04981119Sacituzumab Tirumotecan (MK-2870) Plus Pembrolizumab Versus TPC in TNBC Who Did Not Achieve pCR (MK-2870-012)
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 25, 2026 · NCT06393374A Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Triple-Negative Breast Cancer (MK-2870-011/TroFuse-011)
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 25, 2026 · NCT06841354Lifestyle, Exercise, And Nutrition (LEAN) Trial on Pathologic Complete Response in TNBC
Recruiting
Ages 18 and older · Women · Updated Sep 25, 2026 · NCT07066189Genomically Guided Radiation Therapy in the Management of Triple Negative Breast Cancer
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Sep 25, 2026 · NCT05528133A Study of KIVU-107 in Participants With Locally Advanced or Metastatic Solid Tumors
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Sep 24, 2026 · NCT07229313Intratumoral N17350 in Advanced Solid Tumors
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Sep 23, 2026 · NCT07339176A Study to Evaluate the Safety, Tolerability, Drug Levels, and Preliminary Efficacy of BMS-986507 Combinations in Adult Participants With Advanced Solid Tumors
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Sep 23, 2026 · NCT06618287Evaluate BL-B01D1 in Patients With Metastatic or Unresectable Non-Small Cell Lung Cancer (NSCLC) and Other Solid Tumors
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Sep 21, 2026 · NCT05983432Evolutionary Clinical Trial for Novel Biomarker-Driven Therapies
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Sep 18, 2026 · NCT07340541A Study of SHY-ONC6, a Novel Proteasome Inhibitor, in Adults With Advanced or Metastatic Solid Tumors
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Sep 18, 2026 · NCT07705334A Study of [225Ac]Ac-AKY-1189 in Patients With Solid Tumors
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Sep 17, 2026 · NCT07020117Neoadjuvant INBRX-106 in Combination With Pembrolizumab for Stage II/III TNBC Patients
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Sep 16, 2026 · NCT06353997From ClinicalTrials.gov, data retrieved Oct 5, 2026. Each study sets its own eligibility; the study team decides who can join.